An indirect contribution of Hsp90 in the autoimmune process was confirmed in experimental preclinical studies using Hsp90 inhibitors, belonging solely to the N-terminal binding type, which seem to be more attractive for the treatment of autoimmune diseases due to the activation of an HRS [10,23]. This evidence concerns the gene HSP90AA1 and autoimmune disease.